

Martin W Hoyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/284113/publications.pdf>

Version: 2024-02-01

35
papers

1,252
citations

394421

19
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

1826
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia. <i>Pharmacoeconomics</i> , 2022, 40, 807-821.	3.3	12
2	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2021, 25, 1-248.	2.8	7
3	Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2019, 23, 1-226.	2.8	8
4	Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. <i>Pharmacoeconomics</i> , 2018, 36, 837-851.	3.3	18
5	Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 39-49.	3.3	1
6	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 429-432.	2.1	12
7	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-326.	2.8	21
8	Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30% Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 363-373.	3.3	6
9	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-294.	2.8	24
10	The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 392 T 1-588.	2.8	15
11	Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. <i>Health Technology Assessment</i> , 2016, 20, 1-594.	2.8	42
12	A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 313.	2.6	37
13	A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. <i>Health Technology Assessment</i> , 2014, 18, 1-406.	2.8	98
14	Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer. <i>Value in Health</i> , 2013, 16, 288-296.	0.3	36
15	Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. <i>Age and Ageing</i> , 2013, 42, 14-20.	1.6	82
16	EVOLUTION OF A COST-UTILITY MODEL OF DONEPEZIL FOR ALZHEIMER'S DISEASE. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 147-154.	0.5	4
17	Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2011, 29, 1-15.	3.3	42
18	Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia. <i>Value in Health</i> , 2011, 14, 1057-1067.	0.3	29

#	ARTICLE	IF	CITATIONS
19	Improved curve fits to summary survival data: application to economic evaluation of health technologies. <i>BMC Medical Research Methodology</i> , 2011, 11, 139.	3.1	233
20	Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma. <i>Value in Health</i> , 2010, 13, 55-60.	0.3	22
21	Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma. <i>Value in Health</i> , 2010, 13, 61-68.	0.3	52
22	Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses. <i>Value in Health</i> , 2010, 13, 885-892.	0.3	11
23	Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts. <i>Medical Decision Making</i> , 2010, 30, 426-437.	2.4	27
24	Maximum feasible distance of windborne cross-pollination in <i>Brassica napus</i> : A "mass budget" model. <i>Ecological Modelling</i> , 2009, 220, 1090-1097.	2.5	7
25	Future Drug Prices and Cost-Effectiveness Analyses. <i>Pharmacoeconomics</i> , 2008, 26, 589-602.	3.3	45
26	THE EFFECT OF WIND DIRECTION ON CROSS-POLLINATION IN WIND-POLLINATED GM CROPS. , 2007, 17, 1234-1243.		34
27	EFFECT OF POLLINATOR ABUNDANCE ON SELF-FERTILIZATION AND GENE FLOW: APPLICATION TO GM CANOLA. <i>Ecological Applications</i> , 2007, 17, 2123-2135.	3.8	53
28	A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow. <i>Journal of Theoretical Biology</i> , 2007, 248, 154-163.	1.7	9
29	When corridors work: Insights from a microecosystem. <i>Ecological Modelling</i> , 2007, 202, 441-453.	2.5	9
30	Global Warming, Human Population Pressure, and Viability of the World's Smallest Butterfly. <i>Conservation Biology</i> , 2005, 19, 1113-1124.	4.7	35
31	Experimentally fragmented communities are more aggregated. <i>Journal of Animal Ecology</i> , 2005, 74, 430-442.	2.8	5
32	Mixed effects of habitat fragmentation on species richness and community structure in a microarthropod microecosystem. <i>Ecological Entomology</i> , 2005, 30, 684-691.	2.2	21
33	Causes of the species-area relationship by trophic level in a field-based microecosystem. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2004, 271, 1159-1164.	2.6	49
34	T Helper Cell Type 2 Responsiveness Predicts Future Susceptibility to Gastrointestinal Nematodes in Humans. <i>Journal of Infectious Diseases</i> , 2004, 190, 1804-1811.	4.0	110
35	Species richness of moss landscapes unaffected by short-term fragmentation. <i>Oikos</i> , 2004, 105, 359-367.	2.7	36